Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23069137 | 0.89 | HTR1B (0.37) | HTR1BSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL113567 | 0.82 | TAAR1 (0.57) | HTR1BSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL15902430 | 0.82 | TAAR1 (0.57) | HTR1BSLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL23069122 | 0.80 | SLC6A4 (0.36) | SLC6A4SLC6A2SLC6A3TAAR1CYP2D6 | |
| SCHEMBL715095 | 0.77 | SIGMAR1 (0.45) | SLC6A4SLC6A2SLC6A3TAAR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL5301739 | 0.76 | SIGMAR1 (0.44) | SLC6A4SLC6A2SLC6A3TAAR1CYP2D6 | |
| SCHEMBL1316541 | 0.76 | TAAR1 (0.55) | SLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL7317921 | 0.75 | LOXL2 (0.35) | HTR1BSLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL2418814 | 0.75 | SIGMAR1 (0.48) | SLC6A4SLC6A2SLC6A3TAAR1CYP2D6 | |
| SCHEMBL25080230 | 0.75 | TAAR1 (0.68) | HTR1BSLC6A4SLC6A2SLC6A3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130312-A1 | Method for the detection of compounds comprising methylenedioxyphenyl and testing kit for the same | GLATTSTEIN BARUCH (IL) | 2005-06-16 | — | — | US | claimed |
| WO-2003052426-A1 | A METHOD FOR THE DETECTION OF COMPOUNDS COMPRISING METHYLENEDIOXYPHENYL AND TESTING KIT FOR THE SAME | GLATTSTEIN ORA (IL) | 2003-06-26 | — | — | WO | claimed |
| US-12043605-B2 | Deuterated empathogens | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4392028-A1 | DEUTERATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240189296-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240122914-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240124411-A1 | Deuterated Empathogens | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240122913-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240108640-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS LLC (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240082274-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | TURTLE BEAR HOLDINGS, LLC | 2024-03-14 | — | — | US | disclosed |
| EP-4333838-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | Turtle Bear Holdings, LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-1167976-B1 | Immunoassay for the detection of amphetamines and derivatives thereof | ROCHE DIAGNOSTICS GMBH (DE) | 2007-12-05 | — | — | EP | disclosed |
| US-20070148660-A1 | Treatment of maladaptive substance use with H-ras antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-06-28 | — | — | US | disclosed |
| US-20060258647-A1 | Treatment of maladaptive substance use with cholecystokinin (CCK) antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-11-16 | — | — | US | disclosed |
| US-20060178307-A1 | Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-08-10 | — | — | US | disclosed |
| US-6946547-B2 | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds | MICROGENICS CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| US-20050130312-A1 | Method for the detection of compounds comprising methylenedioxyphenyl and testing kit for the same | GLATTSTEIN BARUCH (IL) | 2005-06-16 | — | — | US | disclosed |
| US-20030207469-A1 | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds | MICROGENICS CORPORATION (US) | 2003-11-06 | — | — | US | disclosed |
| WO-2003052426-A1 | A METHOD FOR THE DETECTION OF COMPOUNDS COMPRISING METHYLENEDIOXYPHENYL AND TESTING KIT FOR THE SAME | GLATTSTEIN ORA (IL) | 2003-06-26 | — | — | WO | disclosed |
| EP-1167976-A2 | Immunoassay for the detection of amphetamines and derivatives thereof | BOEHRINGER MANNHEIM GMBH (DE) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082274-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | MAOB, TPSG1, TPSB2 | HTR1B 9/4885SLC6A4 1378/4885SLC6A2 2261/4885 |
| US-20030207469-A1 | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds | CES2, DNPEP, HLA-A | HTR1B 1602/4885SLC6A4 208/4885SLC6A2 240/4885 |
| US-12043605-B2 | Deuterated empathogens | SLC18A2, SLC6A3, GAP43 | HTR1B 52/4885SLC6A4 10/4885SLC6A2 5/4885 |
| US-20060178307-A1 | Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor | HCRTR2, HCRTR1, GRIN2B | HTR1B 133/4885SLC6A4 234/4885SLC6A2 116/4885 |
| US-20240122914-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1B 1/4885SLC6A4 62/4885SLC6A2 168/4885 |
| US-20240108640-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1B 1/4885SLC6A4 62/4885SLC6A2 168/4885 |
| US-20240124411-A1 | Deuterated Empathogens | SLC18A2, SLC6A3, GAP43 | HTR1B 52/4885SLC6A4 10/4885SLC6A2 5/4885 |
| US-20240122913-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1B 1/4885SLC6A4 62/4885SLC6A2 168/4885 |
| US-20240189296-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR1B 1/4885SLC6A4 62/4885SLC6A2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.